After receiving one of a dwindling number of COVID-era FDA emergency authorizations earlier this year, BD has converted its combination respiratory virus test to a full regulatory green light. The ...
We are maintaining our $306 fair value estimate for narrow-moat Becton, Dickinson as we update our model following fiscal third-quarter results and updated full-year guidance. BD increased its revenue ...
BD’s new MiniDraw diagnostic devices could let pharmacists—and, one day, maybe patients—manage blood testing needs and monitor health conditions. BD received its FDA authorizations for two blood draw ...
FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results